News

This twice-a-year shot to prevent HIV could stop transmission — if people can get it
The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...
The New Times on MSN2h
WHO guidelines for 6-month HIV prevention drug to be released in Kigali
The approval of Lenacapavir – a twice-yearly antiviral HIV-preventing medication marketed under the brand name Yeztugo – by the US Food and Drug Administration (FDA), has been welcomed by the global ...
The American Journal of Managed Care1d
Lenacapavir Offers Promising Step Forward in HIV Prevention: Q&A With Onyema Ogbuagu, MBBCh, FACP, FIDSA
The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across ...
Managed Healthcare Executive19h
With Lenacapavir 'You've Basically Got a Vaccine.' But Reaching the People Who Would Benefit Is Difficult, Says Gates Foundation Expert
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...
Health Affairs2d
A Perfect Storm: “Gamechanger” HIV Prevention Medicine Launches In The Midst Of Health System And Public Health Cuts
This month, lenacapavir is expected to receive FDA approval for pre-exposure prophylaxis (PrEP). It could very well be that ...
Gilead's HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: Report
Lenacapavir, a twice-yearly HIV prevention shot by Gilead, could be produced for $25 a year but may sell for $25K, raising ...
HIV: As Scientists Inch Closer to a Vaccine, Cuts to Funding Could Stall Progress
The Trump administration's plan to cut funding for HIV vaccine research comes at a time when the field is making substantial ...